



1730 5 JUN 22 P2:18

MAY 24 2005

Mr. Ronald G. Sturtz
Founder
Lidtke Technologies Corporation
3202 S. Fair Lane
Tempe, Arizona 85282

Dear Mr. Sturtz:

This is in response to your letter of May 11, 2005 to the Food and Drug Administration (FDA) pursuant to 21 U.S.C. 343(r)(6) (section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (the Act)). Your submission states that Lidtke Technologies Corp. is making the following claims, among others, for the product **DiabeStat™**:

“[F]or the lowering of peak postprandial blood glucose levels...lowering cholesterol, triglycerides...among individuals with elevated levels.”

“[C]onsumption of one capsule before each meal has resulted in very significant reduction in glucose...cholesterol, triglycerides...among individuals with high initial levels.”


21 U.S.C. 343(r)(6) makes clear that a statement included in labeling under the authority of that section may not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases. The statements that you are making for this product, including the name of the product (DiabeStat) which includes a recognizable root of a disease name (i.e., diabetes), suggests that it is intended to treat, prevent, or mitigate diseases, such as diabetes and other disorders of blood glucose regulation and hypercholesterolemia. These claims do not meet the requirements of 21 U.S.C. 343(r)(6). These claims suggest that this product is intended for use as a drug within the meaning of 21 U.S.C. 321(g)(1)(B), and that it is subject to regulation under the drug provisions of the Act. If you intend to make claims of this nature, you should contact FDA's Center for Drug Evaluation and Research (CDER), Office of Compliance, HFD-310, Montrose Metro II, 11919 Rockville Pike, Rockville, Maryland 20852.

97S 0163 LET 829

Page 2 - Mr. Ronald G. Sturtz

Please contact us if we may be of further assistance.

Sincerely yours,



Susan J. Walker, M.D.
Director
Division of Dietary Supplement Programs
Office of Nutritional Products, Labeling
and Dietary Supplements
Center for Food Safety
and Applied Nutrition

Copies:

FDA, Center for Drug Evaluation and Research, Office of Compliance, HFD-310
FDA, Office of the Associate Commissioner for Regulatory Affairs, Office of
Enforcement, HFC-200
FDA, Los Angeles District Office, Office of Compliance, HFR-PA240



9/C 36

May 11, 2005

Food and Drug Administration
Office of Nutritional Products,
Labeling and Dietary Supplements (HFS-810)
Center for Food Safety and Applied Nutrition
200 C Street, SW
Washington, DC 20204

MAY 19 2005

Dear Sirs:

Notice is hereby given pursuant to the requirements of section 403(r)(6) (21 U.S.C. 343(r)(6)) of the Federal Food, Drug, and Cosmetic Act and in accordance with the requirements of 21 CFR 101.93, that Lidtke Technologies Corp., 3202 S. Fair Lane, Tempe, AZ 85282 has commenced marketing a dietary supplement bearing the following statements on the label and/or in the labeling:

(text of claim) "Introducing a patented product for the lowering of peak postprandial blood glucose levels, the reduction of urea formation, and the lowering of cholesterol, triglycerides, and homocysteine levels among individuals with elevated levels. This revolutionary product is a natural blend of nutrients, available in convenient capsule form, and is supported by three patents. In preliminary tests, the consumption of one capsule before each meal has resulted in very significant reduction in glucose, BUN, cholesterol, triglycerides, and homocysteine among individuals with high initial levels.

U.S. Patent 6,602,909
U.S. Patent 5,559,142
U.S. Patent 3,080,234"

DiabeStat™ (name of supplement)

Lidtke Technologies Corp. (brand name)

The undersigned certifies that the information contained in this notice is complete and accurate and that Lidtke Technologies Corp. has substantiation that the statement is truthful and not misleading.

Yours truly,

Ronald G. Sturtz
Founder

#1184